TY  - JOUR
PY  - 2006//
TI  - Cost-effectiveness strategies to treat osteoporosis in elderly women
JO  - Southern medical journal
A1  - Pfister, Alfred K.
A1  - Welch, Christine A.
A1  - Lester, Melissa D.
A1  - Emmett, Mary K.
A1  - Saville, Paul D.
A1  - Duerring, Shea A.
SP  - 123
EP  - 131
VL  - 99
IS  - 2
N2  - BACKGROUND: Comparing the cost-effectiveness of various antiosteoporotic drugs has not been defined. METHODS: We determined the cost-effectiveness of calcitonin, raloxifene, bisphosphates and PTH in a base-case cohort of women aged 65 or older with osteoporosis. After bone densitometry, women were stratified into groups of treatment or no treatment. Our outcome goal was a value of dollars 100,000 or less per quality-adjusted life years (QALY). A sensitivity analysis varied nonvertebral fracture reduction and compliance between the two most effective strategies to test various cost per QALY thresholds. RESULTS: Bisphosphonates displayed the most favorable incremental cost saving and prevented more fractures in our base-case analysis. In a sensitivity analysis, virtually all values of bisphosphonates were under dollars 100,000 per QALY and parathyroid hormone (PTH) was between dollars 100,000 and dollars 200,000 per QALY. CONCLUSIONS: Only bisphosphonates are cost-effective for fracture prevention in osteoporotic women aged 65 or older and this economic advantage is also maintained in subsets who have a lower relative risk of future fracture.<p /> <p>Language: en</p>
LA  - en
SN  - 0038-4348
UR  - http://dx.doi.org/
ID  - ref1
ER  -